Trials / Unknown
UnknownNCT01435135
Study of Late Boost Strategies for HIV-uninfected Participants From Protocol RV 144
Randomized, Double Blind Evaluation of Late Boost Strategies for HIV-uninfected Participants in the HIV Vaccine Efficacy Trial RV 144: "Aventis Pasteur Live Recombinant ALVAC-HIV (vCP1521) Priming With VaxGen gp120 B/E (AIDSVAX B/E) Boosting in HIV-uninfected Thai Adults"
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 162 (estimated)
- Sponsor
- U.S. Army Medical Research and Development Command · Federal
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess safety and tolerability of late boost regimens of AIDSVAX B/E alone, ALVAC-HIV alone, or ALVAC-HIV/AIDSVAX B/E combination in HIV-uninfected participants from RV 144.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ALVAC-HIV | 1 mL per injection containing 10\^6 CCID50/dose administered |
| BIOLOGICAL | AIDSVAX B/E | 1 mL per injection (300 ug dose/antigen for a total of 600ug/dose administered) |
| BIOLOGICAL | ALVAC-HIV Placebo | 1 ml per injection |
| BIOLOGICAL | AIDSVAX B/E Placebo | 1 ml per injection |
Timeline
- Start date
- 2012-04-01
- Primary completion
- 2021-07-01
- Completion
- 2021-07-01
- First posted
- 2011-09-15
- Last updated
- 2020-11-03
Locations
2 sites across 1 country: Thailand
Source: ClinicalTrials.gov record NCT01435135. Inclusion in this directory is not an endorsement.